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Abstract
Nearly a half-century ago, the thrice-weekly hemodialysis schedule was empirically established as
a means to provide an adequate dialysis dose while also treating the greatest number of end-stage
renal disease patients using limited resources. Landmark trials of hemodialysis adequacy have
historically been anchored to thrice-weekly regimens, but a recent randomized controlled trial
demonstrated that frequent hemodialysis (six times per week) confers cardiovascular and survival
benefits. Based on these collective data and experience, clinical practice guidelines advise against
a less than thrice-weekly treatment schedule in patients without residual renal function, yet
provide limited guidance on the optimal treatment frequency when substantial native kidney
function is present. Thus, during the transition from Stage 5 chronic kidney disease to end-stage
renal disease, the current paradigm is to initiate hemodialysis on a “full dose” thrice-weekly
regimen even among patients with substantial residual renal function. However, emerging data
suggests that frequent hemodialysis accelerates residual renal function decline, and infrequent
regimens may provide better preservation of native kidney function. Given the high mortality rates
during the first 90 days of hemodialysis and the survival benefits of preserved native kidney
function, initiation with twice-weekly treatment schedules (“infrequent hemodialysis”) with an
incremental increase in frequency over time may provide an opportunity to optimize patient
survival. This review outlines the clinical benefits of post-hemodialysis residual renal function,
studies of twice-weekly treatment regimens, and the potential risks and benefits of infrequent
hemodialysis.
Over 380,000 people in the US receive hemodialysis (HD) for end-stage renal disease
(ESRD), among whom approximately 105,000 are newly initiated on therapy.1 ESRD
patients have a 7-fold higher risk of death compared to the general population,1 and the first
6 months following dialysis initiation represents a critical transition period during which
there is a heightened mortality risk.2
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Early recommendations from the 1997 Kidney Disease Outcomes Quality Initiative
(KDOQI) Hemodialysis Adequacy Group supported dialysis initiation at a glomerular
filtration rate (GFR) of approximately 10ml/min/1.73m2.3 Updated 2006 KDOQI guidelines
have subsequently advised that dialysis initiation may be warranted at higher levels of GFR
(<15ml/min/1.73m2) in the context of symptoms or declining health related to loss of kidney
function.3 In fact, 29% and 16% of patients initiate dialysis with an estimated GFR (eGFR)
of 10 to <15ml/min/1.73m2 and >15ml/min/1.73m2, respectively.1 Residual renal function
(RRF) at HD commencement may significantly contribute to solute clearance and fluid
balance,4–6 and recent data suggests that preservation of urine output (UOP) is associated
with a survival benefit.7 Although aggressive measures are taken to preserve RRF in the pre-
dialysis and peritoneal dialysis (PD) settings, there is comparatively less focus on the
protection of RRF after HD initiation. In comparison to PD, HD has been shown to result in
a more rapid decline of RRF, which may be due to intradialytic hypotension, renal ischemia,
and exposure to nephrotoxic inflammatory mediators during treatment.8,9 Yet some studies
have shown that RRF is better preserved among HD patients than previously believed, with
up to 70% and 14–20% of HD patients retaining RRF after 1 and 3 to 5 years of therapy,
respectively.10 Indeed, KDOQI guidelines have ranked preservation of RRF in HD as a
grade A recommendation and have emphasized clinical outcomes investigation on RRF as a
critical research priority.11
Despite these recommendations, the current US paradigm is to initiate HD patients on “full-
dose,” thrice-weekly therapy irrespective of RRF and to continue the same frequency of
treatment even after RRF has declined. Within US and European prevalent HD cohorts,
limited data suggest that ~4% of patients or less are on twice-weekly therapy.12,13 In
contrast, data from non-Western countries suggest that prescription of twice-weekly HD is
highly prevalent (9% of prevalent and 25% of incident patients in Japan,14 43% of prevalent
patients in Iran,15 and 75% of prevalent patients in Sudan16). Although decisions to
administer once- or twice-weekly treatment may stem from dialytic resource and financial
constraints, emerging data suggest that, in comparison to thrice-weekly therapy, “infrequent
dialysis” does not confer greater mortality risk13,17 and may in fact be associated with
greater conservation of RRF.18 These findings provide incentive to reevaluate twice-weekly
therapy as a new paradigm for HD initiation. Although some experts have suggested that
twice-weekly therapy may be acceptable in the context of substantial RRF,19 studies of HD
adequacy have historically focused on thrice-weekly regimes in cohorts without RRF.20,21
Given the impact of RRF on survival, twice-weekly therapy may provide an opportunity to
reduce the markedly high mortality rates observed during the transition period from Stage 5
chronic kidney disease (CKD) to ESRD.
History of Thrice-Weekly Therapy
Historical narratives indicate that the frequency and duration of HD prescribing patterns
were empirically determined when this therapy first came into use following Scribner’s
invention of a permanent access device at the University of Washington in 1960.22,23 The
first chronic HD patients in Seattle dialyzed once every 5 to 7 days until symptoms of
uremia recrudesced. The development of malignant hypertension due to hypervolemia and
uremia-associated peripheral neuropathy necessitated an intensification of treatment to
twice-weekly therapy. However, the 12 to 20 hour twice-weekly schedule proved to be
burdensome on patients and families, and a 6 to 8 hour thrice-weekly overnight schedule
was subsequently adopted in Seattle based on early experiences with overnight HD first
developed by Shaldon in London.24 When the Medicare ESRD Program came into being in
1973, thrice-weekly dialysis was the usual practice and provided a concession between
delivery of adequate therapy and treatment of the most patients using limited resources.23
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Hemodialysis Adequacy: Landmark Studies and Clinical Practice
Guidelines
Landmark studies that have sought to define the optimal dialysis dose have largely focused
on thrice-weekly regimens. In the first endeavor to establish an individualized, quantitative
approach to dialysis prescription, the US National Cooperative Dialysis Study (NCDS)
randomized patients using a 2 × 2 factorial design to two time-averaged blood urea nitrogen
targets (50 vs 100 mg/dl) and two dialysis session lengths (2.5–3.5 vs 4.5–5.0 hours).18
Although the study demonstrated that a higher dialysis dose was associated with clinical
benefit, the frequency of HD was fixed as a thrice-weekly schedule at the time of the
protocol design to avoid the complexity of dealing with a variable that might vary across
centers. Following the establishment of kt/v urea as an important predictor of clinical
outcomes, the HEMO trial demonstrated that higher vs lower dialysis doses (single pool kt/v
[spKt/v] 1.25 vs 1.65) conferred similar outcomes, but in this study dialytic prescriptions
were also anchored to thrice-weekly schedules.11 Notably, the NCDS and HEMO cohorts
were both restricted to patients with minimal to absent RRF (creatinine clearance ≤3ml/min
and urea clearance≤1.5ml/min per 35L body water, respectively), thus reducing
generalizability to those with preserved RRF.
Following the HEMO study, efforts to define optimal HD adequacy have shifted from
augmenting the per-session dialytic dose to examining the impact of treatment duration and
frequency on outcomes. The Frequent Hemodialysis Network (FHN) Daily trial randomized
patients to frequent HD (6 times/week) and conventional HD (3 times/week) and
demonstrated that those in the former group had significant benefits with respect to the
composite primary outcome of death and 12-month change in left ventricular mass (with the
majority of the treatment effect on the latter outcome given the low death rates), control of
hypertension, and hyperphosphatemia.25 Although a higher number of access-related
complications were observed in the frequent HD arm, there were no differences in terms of
other secondary outcomes such as cognitive performance, depression, nutritional markers
(eg, serum albumin) or use of erythropoietin-stimulating agents (ESAs). Although this study
demonstrated a number of benefits on primary and secondary outcomes, it was not designed
to evaluate the impact of treatment frequency among patients transitioning from Stage 5
CKD to ESRD with substantial RRF. Patients with urea clearance cutoffs <3ml/min/35L
body water were excluded, and the vast majority of patients were anuric (60.0% and 72.0%
in the conventional and frequent HD groups, respectively).
The most recent KDOQI guidelines recommend that the minimally adequate and target
dialysis doses for patients without substantial RRF (residual urea clearance of <2ml/min/
1.73m2) is an spKt/v of 1.2 to 1.4 per session, respectively, and advise against prescribing
less than thrice-weekly therapy.11 In patients with a residual urea clearance of ≥2ml/min/
1.73m2, allowances are made for a dose reduction to 60% of the minimum target of those
without RRF. However no randomized controlled trials to date have examined the
prognostic implications of reduction of dialysis dose or frequency in patients with
substantial RRF, nor do current practice guidelines define the optimal frequency of therapy
in this context.
Importance of Residual Renal Function
In stage 5 CKD and ESRD, UOP may variably be present at low levels of GFR due to 1) a
urea osmotic diuresis, 2) volume expansion associated with sodium retention, and 3) tubular
damage impairing sodium and water reabsorption.26–28 Hence a rapid reduction in UOP may
be observed upon commencement of dialysis with the subsequent reversal of volume
expansion and high urea load per nephron. Earlier studies have shown that HD patients
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experience an accelerated loss of RRF compared to those on PD (−3.6ml/min/1.73m2 vs
−4.2ml/min/1.73m2 during the first 1 year of dialysis, respectively) which may be related to
greater intradialytic hypotension resulting in renal ischemia and acute tubular necrosis, and
activation of nephrotoxic inflammatory mediators (e.g., exposure to dialysis tubing and
impurities, previously used bioincompatible membranes).8,9 However, it should be noted
that with the advent of biocompatible membranes, replacement of vasodilatory acetate
buffer with bicarbonate, and secular trends towards earlier initiation of dialysis therapy,
contemporary HD cohorts may experience greater preservation of RRF than previously
observed.29–31 A small study of 11 patients on twice-weekly HD demonstrated that urine
production, inulin clearance, and fractional sodium clearance steadily increased over the 3-
day interdialytic interval.32 Although this may be a result of increased osmotic load and
extracellular volume accumulation over the long interdialytic period, examination of the
impact of infrequent dialysis on long term RRF preservation is warranted.
RRF preservation following dialysis initiation has important implications for clinical
outcomes in the ESRD population. At very low levels of GFR (~4–5ml/min/1.73m2) in
ESRD patients, RRF has a significant impact on solute clearance given its continuous
nature33; it may also provide greater clearance of middle and large molecular weight solutes
in comparison to dialytic therapies.6,34,35 RRF also improves fluid balance,6,10,36 reducing
the risk of large interdialytic weight gains and subsequent high ultrafiltration requirements,
left ventricular hypertrophy, intradialytic hypotension, myocardial stunning, and
cardiovascular mortality. In the PD population, RRF’s association with improved survival is
well established. In a reanalysis of the CANUSA study, each 5L/week per 1.73m2 increment
in RRF and each 250ml increase in UOP was associated with a 12% and 36% reduction in
mortality, respectively.37 Similarly, in the ADEMEX trial, each 10L/week per 1.73m2
increment in RRF was associated with an 11% reduction in mortality.38 In both studies,
peritoneal clearance was not associated with survival.
Recent observational data also suggests that RRF is associated with improved survival in
HD patients. In a study of 650 incident HD patients, Vilar et al demonstrated that the
presence of RRF was associated with improved survival at 6, 12, and 24 months follow-up
in multivariable adjusted analyses; notably, patients with preserved RRF had lower kt/v
values suggesting that native renal clearance was superior to dialytic clearance with respect
to mortality benefit.10 In an evaluation of 740 incident HD patients from the NECOSAD
cohort, each 1L/week increase in clearance was associated with a 56% reduction in risk of
death, and RRF was a stronger predictor of survival than dialytic clearance.39 Most recently,
in a study of 734 incident HD patients from the CHOICE cohort, preservation of UOP after
1 year was associated with lower all-cause mortality and a trend towards reduced
cardiovascular mortality, and baseline UOP was associated with improved quality of life,
improved cognition, dietary liberalization, and reduced inflammation.7 In both the PD and
HD populations, RRF may be associated with improved nutritional parameters,10,40–42
decreased ESA requirements,10 improved phosphorus43,44 and potassium control,45 and
reduced left ventricular hypertrophy,46 which may serve as underlying mechanistic links
between RRF and improved mortality.
Infrequent Dialysis: Historical Precedents
Emerging data suggests that RRF may be used as a guide to establish and adjust HD
frequency and fluid status monitoring. This concept of “incremental dialysis” was initially
described among PD patients, in whom RRF is critical to solute clearance, fluid balance, and
survival.47,48 The ideal scenario for utilization of incremental dialysis is when significant
RRF is present and can contribute to total renal replacement therapy, which may occur in the
context of 1) HD or PD initiation, 2) resumption of dialysis with renal allograft failure, and
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3) conversion from failing PD to HD.49 Using this approach, the dose of delivered dialysis is
increased as RRF declines in such a manner that the sum of weekly residual renal plus
artificial dialytic clearance is maintained above a certain minimum. Keshaviah et al have
previously defined a urea kinetic model to show how the HD dose can be titrated to
compensate for declining renal function while maintaining a constant total combined dose of
renal and dialytic clearance.50 Using data on RRF decline from a previously described HD
cohort, the authors demonstrated a model in which a hypothetical patient initiates once-
weekly therapy and is gradually increased to twice-weekly and thrice-weekly dialysis as
RRF declines after 5 and 36 months, respectively (Figure 1).
Dietary protein restriction has also been employed as an adjunctive measure to reduce
dialysis frequency in incremental treatment regimes. The Northern Cooperative Study Trial
enrolled 69 patients with a weekly RRF kt/v urea of approximately 0.5 in an integrated diet
dialysis program consisting of once-weekly HD and a low protein diet (0.4g/day)
supplemented with essential amino acids in order to maintain a predialytic BUN of <90mg/
dl.51 After 1 year, there was >50% dropout, and patients developed signs of worsened
anthropometric status (eg, decreased serum creatinine) and uremia progression (eg,
decreased distal nerve conduction velocity) leading authors to advise against broad
application of this management strategy.
Twice-Weekly Therapy and Outcomes
Mortality
To date, there have been a limited number of observational studies that have evaluated the
association between twice-weekly HD therapy and outcomes (Table 1). The sole US study
examining the prognostic implications of twice-weekly therapy was a retrospective
evaluation of 15,543 HD patients from the 1993 US Dialysis Morbidity and Mortality Study
cohort.13 In this study, patients on twice-weekly therapy tended to be of shorter vintage,
older age, female gender, and Caucasian, and at baseline had more favorable nutritional
parameters (higher serum albumin) but worse anthropometric markers (lower serum
creatinine and body mass index). Multivariable adjusted survival analyses restricted to
incident patients demonstrated that twice-weekly therapy was associated with a mortality
reduction that was attenuated with further adjustment for RRF. Examination of prevalent
patients demonstrated that twice-weekly therapy was associated with reduced mortality risk
compared to patients on thrice-weekly therapy; however these analyses did not account for
differences in RRF, and the survival advantage associated with twice-weekly therapy was
likely related to more favorable patient characteristics in the twice-weekly group.
Notably, prevalent patients on twice-weekly therapy had shorter dialysis session lengths and
marginally higher delivered kt/v per session, resulting in lower weekly kt/v compared to
their thrice-weekly counterparts. These findings among prevalent patients are noteworthy as
they suggest that infrequent dialysis despite lower weekly delivered kt/v is not per se
harmful, and that twice-weekly schedules may not only serve as a temporary transition
strategy but also as a long-term dialytic approach.
Similarly, in a smaller but more contemporary cohort of 1288 incident and prevalent HD
patients from the Shanghai Renal Registry, multivariable adjusted survival analyses
demonstrated an equivalent mortality risk between twice-weekly and thrice-weekly patients,
although interpretation is limited by absence of RRF data and residual confounding.17 Case-
mix differences within this cohort (ie, high prevalence of glomerulonephritis and low
prevalence of diabetes and hypertension as the primary cause of kidney disease) may also
limit generalizability to US populations.
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In contrast, other studies from developing countries have shown that twice-weekly therapy is
associated with increased mortality. Data from 2063 incident HD patients in Lithuania
demonstrated that patients on once- and twice-weekly therapy (~36% and 5% of cohort,
respectively) had a nearly two-fold higher risk in mortality compared to those on thrice-
weekly regimens, although there was limited adjustment for covariates that did not include
RRF.52
In another study of 1011 prevalent HD patients in Sudan, a greater proportion of patients on
thrice-weekly therapy survived over a 1-year follow-up period compared to those on twice-
weekly treatment although differences did not reach statistical significance (89% vs 85%,
respectively; p=0.06); however these findings are limited by lack of time-to-event analysis,
residual confounding, and incomplete data on dialysis adequacy or RRF.16 In contrast to the
Dialysis Morbidity and Mortality Study, resource constraints (ie, limited HD accessibility)
among non-US cohorts likely had a stronger influence on decisions to prescribe twice-
weekly therapy regimes than physician- or patient-related factors, and may have also
impacted outcomes.
Residual Renal Function
Given the hastened decline in RRF that may be observed with HD initiation, there has been
increasing interest in how the frequency of dialytic therapy impacts RRF preservation. In a
study of 74 prevalent HD patients in Taiwan who maintained the same HD frequency
without cross-over, the rate of RRF decline was compared among patients on twice vs
thrice-weekly therapy with similar baseline creatinine clearance and UOP levels.18 After a
mean follow-up of 18 months, those on twice-weekly therapy had higher creatinine
clearance and UOP levels and a slower rate of RRF decline compared to their thrice-weekly
counterparts. Additionally, patients on twice-weekly treatment had greater clearance of large
molecular weight solutes (as measured by serum beta-2 microglobulin levels), less
intradialytic hypotension, and fewer hospitalizations for infections; however, no differences
in nutritional or inflammatory parameters, total spKt/v or AV fistula dysfunction were
observed between groups. However, analyses did not account for differences in
demographics or case-mix covariates between the two groups with multivariable adjustment.
Unpublished data from Shanghai have also shown that in a cohort of 165 HD patients,
45.5% received less than thrice-weekly HD; in a subgroup of 51 patients with GFR follow-
up within one year of HD initiation, increased HD frequency was associated with greater
decline in RRF in multivariable adjusted analyses.53
A corollary study from the FHN Daily and companion Nocturnal trials comparing frequent
HD vs conventional HD suggests that the impact of dialytic frequency on RRF decline exists
on a spectrum.54 Among non-anuric patients in the Nocturnal trial arm, patients receiving
frequent HD had a greater decline in RRF as measured by urine volume, urea clearance, and
creatinine clearance compared to those receiving conventional HD at 4 and 12 months
follow-up. Notably, patients in the frequent HD group had a significantly lower nadir in
intradialytic systolic blood pressure compared to the conventional group, suggesting a
hemodynamic etiology as the mechanistic link. However, in the Daily trial aim, there was no
significant difference in RRF at 4 and 12 month follow-up between the frequent HD and
conventional HD patients with non-zero RRF. It should be noted however that the Daily trial
excluded patients with higher levels of RRF in comparison to the Nocturnal trial (urea
clearance cutoffs <3ml/min/35L body water and <10ml/min/35L body water, respectively),
which may have resulted in underpowered analyses with which to ascertain differences
between the frequent and conventional groups in the Daily trial.
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Other Potential Benefits
There may be a number of additional benefits that infrequent treatment confers to incident
HD patients. For example, it has been suggested that frequent therapy may contribute to
malnutrition through dialytic losses of vital nutrients (eg, carnitine, vitamin C).55 However,
inadequate uremic toxin clearance associated with infrequent therapy could theoretically
exacerbate malnutrition, and studies have shown that switching patients from conventional
to daily HD increases appetite and protein intake.56 In a cross-sectional study of 142
prevalent HD patients all with a weekly spKt/v>3.6 from the National Kidney Foundation
dialysis unit of Thailand, analyses unadjusted for difference in patients’ case-mix covariates
or RRF demonstrated no significant differences in anthropometric measurements, laboratory
nutrition markers (ie, serum albumin, total cholesterol, nPNA), or survey-ascertained dietary
protein intake between those receiving twice- and thrice-weekly therapy; notably, twice-
weekly therapy patients reported greater dietary energy intake than thrice-weekly patients.57
As noted above, Taiwanese patients receiving twice-weekly therapy had similar nutritional
parameters (serum albumin, normalized protein catabolic rate) as their thrice-weekly
counterparts.18
Extrapolation of findings from studies evaluating greater than thrice-weekly HD regimens
suggest that more frequent HD regimens may be associated with greater vascular access
loss25 (possibly due to inflammation associated with the dialytic procedure and more
frequent access cannulation). Additionally, frequent HD may predispose to increased ESA
resistance and from dialytic blood loss and iron deficiency, and repeated exposure to dialysis
tubing and membranes could potentially increase inflammation, oxidative stress, and
subsequent cardiovascular risks.55 Initiation of HD with twice-weekly schedules and gradual
transition to thrice-weekly therapy as RRF declines may also reduce lifestyle and
employment status interruptions, minimize psychological, and enhance patients’ quality of
life and acceptance of treatment.48,55
It is possible that some patients who undergo an infrequent treatment strategy may be
reluctant to increase HD frequency as RRF declines, resulting in non-compliance and
inadequate dialysis; thus it is imperative that providers and patients have an understanding
that the dialysis frequency and dose will inevitably increase over time.49 Lastly, given the
global epidemic of ESRD, appropriate allocation of infrequent HD to patients with
substantial RRF who can thus achieve adequate total (renal plus dialytic) clearance may
provide the opportunity to allocate limited dialytic resources to a broader population. Further
study of the direct impact of infrequent HD regimens on ESRD patients’ mortality, RRF,
vascular access preservation, cardiovascular outcomes, ESA resistance and usage, quality of
life, and cost-benefits are needed.
Potential Harms of Infrequent Dialysis
Despite achievement of adequate or supratherapeutic spKt/v targets with adjunctive native
solute clearance, there may be certain scenarios in which intermittent infrequent HD is ill-
advised. For example, patients with excess interdialytic weight gains may not be suitable for
less than thrice-weekly HD schedules, irrespective of presence of RRF.17 High interdialytic
weight gains and chronic extracellular fluid volume overload predispose to hypertension,
left ventricular hypertrophy, and congestive heart failure which negatively impact dialysis
patients’ survival.58 Additionally, higher interdialytic weight gains in the context of
infrequent HD may necessitate high ultrafiltration rates that result in intradialytic
hypotension, myocardial stunning, cardiac ischemia,59 and inability to achieve dry weight
due to cessation of ultrafiltration and infusion of saline that perpetuating the volume
overload cycle.60 Hence, “permissive hypervolemia” with the intention in preserving native
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kidney function to survival benefit may have detrimental effects on cardiovascular health
that offset the benefits of RRF.6
Protracted interdialytic intervals with infrequent HD may also pose harm. Data from 32,065
US patients from the ESRD Clinical Performance Measures Project has shown higher rates
of death and cardiovascular-related hospital admissions on the day after the long 2-day
interdialytic interval presumably due to accumulation and/or rapid dialytic reduction of
electrolytes, fluid, and various uremic toxins.61 Although RRF data was not available, >75%
of patients had a vintage of ≥1 year, and it is likely that the majority of patients were anuric
and lacked adjunctive capacity to clear uremic toxins and maintain fluid and electrolyte
balance. Data from 22,163 patients from the Dialysis Outcomes and Practice Patterns Study
showed similar findings in non-US populations in Europe and Japan.62 Nonetheless
protracting the long interdialytic interval from 2 days with thrice-weekly dialysis to 3–4
days with infrequent HD may be deleterious in patients who are prone to hyperkalemia and
other electrolyte derangements.
Lastly, it is possible that some subgroups may be unsuitable for twice-weekly therapy due to
higher dialysis dose requirements. In a subgroup analysis of the HEMO study, women
experienced a survival benefit with higher dialysis dose whereas men did not.20
Additionally, patients with a high burden of comorbidities or hypercatabolic state may
require more frequent HD regimens to maximize solute clearance. Thus prescribing HD
frequency using an individualized approach in lieu of a “one size fits all” strategy, and
examining the differential effects of infrequent therapy across subgroup populations is
warranted.
Conclusion
For the past 50 years, usual practice has been to initiate HD with a thrice-weekly treatment
schedule irrespective of patients’ RRF. The presence of native kidney function at even low
levels provides fluid and electrolyte balance, and it is associated with more favorable quality
of life indicators and survival benefit. However, native kidney function is often neglected
following HD initiation, and there are a paucity of studies examining ways to preserve this
intrinsic source of solute clearance and ultrafiltration. In contrast, PD initiation has typically
employed a more individualized approach that incorporates both native kidney and dialysis
clearance into the total weekly clearance target until RRF is lost at which time the dialytic
prescription is intensified. Ideally, assessment of HD adequacy should encompass per-
session dialysis dose and length, frequency of treatment, and the contribution of RRF. It is
our opinion that initiating HD with a twice-weekly regimen with an incremental increase
over time may provide an opportunity to preserve RRF, optimize quality of life, and
decrease mortality. Emerging observational data that suggests infrequent HD schedules may
be beneficial, but interpretation is limited by residual confounding, lack of data on native
kidney function, and inclusion of anuric prevalent HD patients. At this time, randomized
controlled trials are needed to determine the adequacy, safety, and cost-benefits of
infrequent HD regimens.
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Figure 1.
Urea kinetic model in which a hypothetical patient initiates once-weekly therapy and is
gradually increased to twice-weekly and thrice-weekly dialysis as residual renal function
declines after 5 and 36 months, respectively. The renal and dialytic contributions to the dose
of dialysis are shown as a function of the months on dialysis, and the total dose of delivered
therapy is fixed at a set kt/v. Taken from Keshaviah PR, Emerson PF, Nolph KD. Timely
initiation of dialysis: a urea kinetic approach. American journal of kidney diseases: the
official journal of the National Kidney Foundation. Feb 1999;33(2):344–348.
Rhee et al. Page 13
Semin Dial. Author manuscript; available in PMC 2014 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Rhee et al. Page 14
Table 1
Summary of observational studies examining the association between infrequent hemodialysis and outcomes.
Study Cohort description n Results
Mortality
Hanson (1999)13 Incident and prevalent
HD
15,067 Incident patients: Twice-weekly treatment similar
mortality risk compared to thrice-weekly treatment.
Prevalent patients: Twice- weekly therapy decreased
mortality risk but unadjusted for RRF.
Lin (2012)17 Incident and prevalent
HD
1288 (multivariable adjusted) Overall cohort: Twice-weekly treatment similar
mortality risk compared to thrice-weekly patients.
Incident patients:
Survival rates between twice and thrice-weekly patients
similar in both subgroups. Prevalent (vintage>5 years)
patients: Survival rates between twice and thrice-weekly
patients similar in both subgroups.
Stankuviene52 (2010) Incident HD 2428 Once and twice-weekly treatment with increased
mortality risk compared to thrice-weekly treatment.
Elamin (2012)16 Prevalent HD 2012 Greater proportion of twice- weekly patients with 1-year
mortality than thrice-weekly patients (but differences not
statistically significant).
Residual Renal Function
Lin (1999)18 Prevalent HD 74 Twice-weekly treatment with greater RRF preservation
than thrice-weekly treatment.
Chen (2012)53 Incident HD 51 Twice-weekly treatment with thrice-weekly treatment.
greater RRF preservation than thrice-weekly treatment.
Daugirdas (2013)54 Prevalent HD 63 (Nocturnal trial)
83 (Daily trial)
Nocturnal trial: Frequent HD with greater RRF decline
than conventional HD.
Daily trial: Frequent HD with similar RRF decline as
conventional HD.
Nutritional Parameters
Supasyndh (2009)57 Prevalent HD 142 Twice-weekly treatment similar nutritional laboratory
parameters and daily protein intake but greater daily
energy intake than thrice-weekly treatment.
Lin (1999)18 Prevalent HD 74 Twice-weekly treatment with similar nutritional
laboratory parameters as thrice-weekly treatment.
Abbreviations: HD, hemodialysis; RRF, residual renal function.
* Unpublished data.
† Comparison between frequent HD (6 times/week) and conventional HD (3 times/week).
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